Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RBC2LCN lectin detects early-stage HER2-positive breast cancer

ABSTRACT: We found that MCF-7 and T-47D or MDA-MB-157 and MDA-MB-231 are rBC2LCN-positive or -negative breast cancer cell lines, respectively. To examine a global gene expression comparison between the rBC2LCN-positive and -negative breast cancer cell lines, DNA microarray analysis was performed.

ORGANISM(S): Homo sapiens

PROVIDER: GSE139670 | GEO | 2020/06/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression analysis of HER2+ breast leptomeningeal carcinomatosis

Project description:Patient-derived primary HER2+ Leptomeningeal carcinomatosis (Lepto) cell lines were established. RNA-seq in various breast cancer cell lines were conducted to characterize the established cell lines. Gene expression analysis clearly indicated thatt Lepto cell lines are transcriptionally different from HER2 positive and negative metastatic breast cancer cell lines such as BT474 and MDA-MB-231 cells.

2021-07-05 | GSE179280 | GEO

Indole-3-Carbinol Preferentially Target ERÎ±-Positive Breast Cancer Cells.

Project description:Indole-3-carbinol (I3C) is a natural anti-carcinogenic compound found at high concentrations in Brassica vegetables. ER-positive cell lines demonstrated the greatest sensitivity to the anti-tumor effects of I3C compared to ER-negative breast cancer cell lines. Gene expression analysis was performed to identify genes and pathways that accounted for sensitivity to I3C. Microarray analysis performed using Illumina HT-12 v4 expression arrays A total of 36 samples were analyzed with six breast cancer cell lines treated with either the vehicle control or the drug Indole-3-carbinol in triplicate. The cell lines were: MCF-7, T47D, ZR751(sensitive to the drug, apoptosis/growth arrest) and MDA-MB-231, MDA-MB-157, and MDA-MB-436 (insensitive to the drug). Sensitive cell lines are of the luminal subtype and insensitive cell lines are of the basal subtype.

2014-08-12 | E-GEOD-55897 | biostudies-arrayexpress

rBC2LCN lectin detects early-stage HER2-positive breast cancer

Project description:rBC2LCN lectin detects early-stage HER2-positive breast cancer

| PRJNA586852 | ENA

Genes induced by partial down-regulation of ARID1A in breast cancer cell

Project description:Development of gene expression signatures for partial downreualtion of ARID1A protein. ARID1A was down-regulated by si-RNA in a breast cancer cell, MDA-MB-157. Subsequently, RNAs was extracted from control siRNA treated cells or partially ARID1A-down regulated cells. cDNAs were synthesized and cRNAs were labeled using low input quick Amp labeling kit (Agilent). Aftere washing and dry, scanned by Agilent Technologies Micorarrray Scanner and calculated using Agilent Feature 10.7.3.1. control siRNA treated MDA-MB-157 breast cancer cells (MOK) and siRNA-midiated ARID1A-downregulated MDA-MB157 breast cancer cells.

2015-09-03 | E-GEOD-72669 | biostudies-arrayexpress

Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells

Project description:We examined gene expression change under amino acid restriction in JPH203 treated MDA-MB-231 and T-47D cells. JPH203 treatment induced endoplasmic reticulum stress response via amino acid starvation stress pathway in both MDA-MB-231 and T-47D cells. Moreover, MDA-MB-231 was upregulated anti-oxidants related genes.

2022-01-26 | GSE173698 | GEO

Genome-wide analysis of GW3965-responsive genes in 4 different breast cancer cell lines, MCF-7, T-47D, SK-BR-3, and MDA-MB-231

Project description:Analysis of differentially expressed genes in response to the LXR agonist GW3965 in the MCF-7, T-47D, SK-BR-3, and MDA-MB-231 breast cancer cell lines. It was previously reported that GW3965 has antiproliferative effects on these 4 different breast cancer cell lines. In the present study, we additionally determine the effects of the LXR ligand on breast cancer cells and determine their mechanism of action in reducing cell proliferation. Total RNA obtained from 4 different breast cancer cell lines (MCF-7, T-47D, SK-BR-3, MDA-MB-231) grown in culture treated with ethanol (control) or GW3965 (GW-treated, experimental) for 48 hours. Triplicates were performed.

2013-07-17 | E-GEOD-34987 | biostudies-arrayexpress

Effects of retinoids on estrogen-receptor-positive and -negative breast carcinoma cells: mRNA profiling

2010-05-21 | GSE18390 | GEO

RNAseq in breast cancer cells with EBF1 knockdown

Project description:Transcriptional analysis of MDA-MB-157 and MDA-MB-436 with EBF1 knockdown

2022-07-08 | GSE195764 | GEO

Effects of retinoids on estrogen-receptor-positive and -negative breast carcinoma cells: mRNA profiling

Project description:The overall study explores differential sensitivity of estrogen-receptor-positive and -negative breast carcinoma cells to retinoids via gene expression and microRNA profiling in MCF7 and MDA-MB-231 cells. This Series reports results of transcriptional profiling of breast carcinoma cell lines comparing the effects of retinoic acid treatment (6 and 48 hours) on estrogen-receptor-positive (MCF7) and estrogen-receptor-negative (MDA-MB-231) cells. mRNA profiling: Retinoic-acid-treated (1microM) vs vehicle-treated cells, two time points (6 and 48h), two cell lines (MCF7 and MDA-MB-231). Two biological replicates for each condition, balanced dye design.

2010-05-21 | E-GEOD-18390 | biostudies-arrayexpress

Newly constructed network models of different WNT signaling cascades applied to breast cancer expression data

Project description:RNA-Seq profiling of MCF-7 and MDA-MB-231. We profiled RNA expression in the estrogen-receptor-positive (ER+) MCF-7 and the triple-negative MDA-MB-231 breast cancer cells. The objective was to find genes differentially expressed between these cell lines as potential drivers of invasiveness of the triple-negative MDA-MB-231. We further utilized the identified differential genes to validate expression-responsive module of non-canonical Wnt signaling pathway.

2016-01-21 | GSE73857 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data